Teva warns 'skinny label' ruling could sow 'competition-killing uncertainty' for generics

As promised back in February, Teva Pharmaceuticals has asked the U.S. Supreme Court to overturn its $235 million loss in the company’s long-running “skinny label” patent feud with GSK.